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mated quality-adjusted life-years (QALYs), number/costs of SREs, and drug/admin-
istration costs for mPC patients receiving denosumab or zoledronic acid for 27
months (trial timeframe) and 60 months. List prices were used in the base case. A
generic zoledronic acid price (53%  list price, per data for now-generic bisphos-
phonates) and discounted prices (–30%) were used for both denosumab and zole-
dronic acid in scenario analyses. Clinical inputs reproduced trial outcomes. QALYs
were estimated via utility weights to time spent in health states (no SRE; SRE;
post-SRE; death). SRE costs and utilities were literature-based. RESULTS: Over 60
months, denosumab resulted in fewer SREs (–0.398), more QALYs (0.0096), and
lower SRE-related costs (–£790). The costs/QALY (drug costs; total costs) over 60
months in the list price scenario (list price for both agents), in the generic zole-
dronic acid after May 2013 pricing scenario, and in the scenario with both agents
discounted after May 2013, were £164,502 (£2369; £1579), £214,707 (£2851;
£2061), and £98,124 (£1732; £942), respectively. Similar results were found over
27 months. CONCLUSIONS: The incremental cost/QALY gained with denosumab
versus zoledronic acid exceeded the traditional £30,000 threshold, thus raising
important questions about denosumab’s health-economic value in mPC.
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OBJECTIVES: Approximately 60% of breast cancer cases are a hormone sensitive.
Tamoxifen (TAM) is most widely used treatment of hormone-dependent breast
cancer. In the last decade, TAM has been surpassed by more effective, but more
expensive Aromatase Inhibitors (AI), new generation of estrogen inhibitors. In Can-
ada, mono and sequential strategies of AI and TAM for treating ER early breast
cancer patients are used widely. Meanwhile, practitioners have not come to a
consensus yet regarding the optimal cost-effective hormone therapy strategy. The
objective of study to assess cost-effectiveness of four hormone strategies (mono
and sequential TAM and AI) currently used for treating ER early breast cancer
patients from the Canadian health care perspective. METHODS: We performed a
cost-effectiveness analysis using a Markov model from a societal perspective with
a lifetime horizon. The base case involved 65-year-old ER hormone sensitive
women with early breast cancer. Probabilistic sensitivity analysis was used to in-
corporate parameter uncertainties. Expected value of perfect information was per-
formed to identify future research directions. Outcomes were quality-adjusted life
years (QALYs) and costs. RESULTS: AI-TAM sequential strategy is dominant be-
cause it is more effective and less costly. Next dominant strategy is TAM-AI, AI
monotherapy is more effective but more costly than standard TAM monotherapy.
AI monotherapy, TAM-AI and AI-TAM sequential therapies reduce recurrence by
8.1%, 5.9% and 5.6% compared to TAM monotherapy. Additional QALY gained from
using new therapies were 0.06 QALYs for AI, 0.08 QALY’s for TAM-AI and 0.16
QALYs for AI-TAM therapies. Using AI monotherapy increased total expected dis-
counted cost by CAD $302 per patient compared to TAM monotherapy, while using
sequential therapies reduced total cost by CAD $62 TAM-AI and CAD $481 for
AI-TAM. CONCLUSIONS: In postmenopausal ER women with hormone sensitive
early breast cancer, adjuvant AI-TAM sequential therapy may be cost effective
from the Canadian health care system perspective.
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OBJECTIVES: Effectiveness of rituximab maintenance treatment among patients
with relapsed follicular lymphoma (FL) has been established in a randomised trial
(EORTC20981). Although trials have been accepted as the golden standard for ef-
fectiveness, results might not be generalisable to real-world patient populations.
Therefore, outcomes research was conducted to calculate real-world cost-effec-
tiveness of second line rituximab maintenance compared to observation in FL
patients in the Netherlands. METHODS: Two Dutch population-based registries
(PHAROS and HemoBase), obtained data on patient characteristics, treatment, and
resource utilisation of patients diagnosed with FL in the past 20 years. Patients
responding to second line chemotherapy were included in the observation or
maintenance group. A Markov model was applied to calculate real-world
cost-effectiveness. RESULTS: Out of 735 FL patients included in the registries, this
study allocated 57 and 49 patients to the observation and maintenance group,
respectively. Median age was similar in both groups (61 years). Differences between
the groups were found for second line treatment with rituximab (77% and 92% in
the observation and maintenance group p0.05) and years since diagnosis
(p0.01). The maintenance group showed higher 3-year overall survival (75% ver-
sus 63%) and longer time till next treatment (p0.01). Compared to the trial, real-
world patients were older and less often diagnosed with stage IV. Real-world pre-
scription of rituximab was comparable to the trial although cycles were prescribed
more frequent. Daily practice data combined with trial efficacy resulted in cost-
effectiveness ratios between €3,614 and €5,246 per life year gained and €3,555 and
€5,156 per quality-adjusted life year. CONCLUSIONS: Real-world FL patients were
not identical to trial patients emphasising the importance of studying real-world
data. However, findings from non-randomised groups should be analysed with
caution, since observed dissimilarities between the groups suggested the represen-
tation of different types of patients. Nevertheless, real-world cost-effectiveness for
second line rituximab maintenance was favourable.
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OBJECTIVES: Maintenance treatment with Rituximab (MabThera) has been shown
a cost-effective and / or cost-saving treatment option, when compared with alter-
native treatment strategies for treating patients with Non-Hodgkins Lymphoma
(NHL) in several countries. The objective of this study is to identify whether main-
tenance with Rituximab in first line NHL patients represents a cost-effective treat-
ment option for the Greek Healthcare system. METHODS: A cost-effectiveness
Markov model that compared maintenance with Rituximab versus observation
was applied after adapting for local cost data from published sources. Clinical data
were derived from PRIMA and EORTC 20981. RESULTS: Patients treated with Ritux-
imab remained in Progression Free state for an additional 1.91 years and displayed
an additional 1.61 QALYs versus observation. Mean Total Cost per patient in the
Rituximab maintenance arm was calculated at €79,721 versus €67,928 in the obser-
vation arm. Mean total cost of PFS including the cost of Adverse Events was €71.95
for the Rituximab group and €57.44 for the observation group. Mean Supportive
Care costs for the Progression-Free state were € 18,193 for patients on Rituximab
and €20,168 for patients on observation. Mean supportive care cost of progression
was € 7,766 for the Rituximab group and €10,483 for the observation group. ICERs for
Rituximab maintenance were €8,679 per QALY gained and €7,866 per LYG gained,
which are both below the common cost-effectiveness thresholds used by Health
Technology Assessment (HTA) agencies worldwide. CONCLUSIONS: Maintenance
treatment with Rituximab is clinically more effective and economically more cost-
effective than existing treatments for patients with NHL in the Greek health care
setting. Full reimbursement of Rituximab maintenance treatment for patients with
NHL by Social Security Funds would constitute an effective use of their – scarce –
resources.
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OBJECTIVES: In the UK, prostate cancer is the most commonly-occurring cancer in
males; it has an incidence rate of 103 per 100,000. First-line therapy for patients
with advanced prostate cancer is commonly a luteinising hormone-releasing hor-
mone (LHRH) agonist. Degarelix is a testosterone-ablating therapy that acts as
gonadotrophin-releasing hormone (GnRH) antagonist. It induces a decrease in both
testosterone and prostate-specific antigen (PSA) levels, without the initial testos-
terone surge which can be associated with LHRH agonist therapies such as leupro-
relin, goserelin and triptorelin. A previous model assessing the cost-effectiveness
of degarelix was published by Lu et al (2011). However, only limited data were
available at the time and here we present a model based on longer term data.
METHODS: A cost-utility model using a cohort state transition structure was de-
veloped to assess the cost effectiveness of degarelix. The 5-year data informing the
model was derived from the Phase III clinical trials (CS21 and CS21a). Advisory
boards conducted with UK clinicians informed the model structure. Patients trans-
ferred through disease states according to their PSA progression – identified by
clinicians as a key indicator of progression to second-line treatment. Adverse
events for which there were statistically significant differences were also included
in the model. A scenario analysis was undertaken where PSA progression was
assumed to be equal for degarelix and leuprorelin, although data indicate a lower
risk with degarelix. RESULTS: Degarelix showed a reduction in costs (£5,152) and
increase in QALYs (0.24) when compared to leuprorelin in the base case. In the
scenario analysis, treatment with degarelix was also dominant. CONCLUSIONS:
Updated modelling undertaken with the most recent data indicates that treatment
with degarelix is dominant – this remains the case when it is conservatively as-
sumed, that PSA progression is not important, contrary to what was informed by
clinicians, and seen in the trial data.
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OBJECTIVES: Personalized medicine tries to select specific subpopulation of pa-
tients by biomarkers to refine therapeutic algorithms. We have performed a cost-
effectiveness analysis to assess incremental cost-effectiveness ratio (ICER) per ra-
diological response (RR) for cetuximab or panitumumab based scheduled as 1st line
therapies for metastatic colorectal cancer (mCRC) patients in Spain. METHODS:
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